Chiome Bioscience News

Chiome Bioscience: Announcements of the exercise of large amounts of subscription rights (with exercise price adjustment clause) in the 21st period.

Aug 14 04:30 ET

Chiome Bioscience: Supplementary information on the financial results for the second quarter of the period ending December 2024.

Aug 13 03:00 ET

Chiome Bioscience: Non-consolidated performance for the 6 months ending on June 30th, 2024 (Japanese accounting standards).

Aug 13 03:00 ET

Chiome Bioscience: Announcements of individual stocks regarding patent assessments in Japan for the combination of humanized DLK-1 antibody and lenvatinib.

Aug 12 19:50 ET

Chiome Bioscience: Announcements of subscription rights (with exercise price adjustment clause) for the 20th and 21st month exercise status

Aug 1 02:00 ET

Chiome Bioscience: Initiation of phase I clinical trial of therapeutic antibody drug conjugate ADCT-701.

Jul 28 23:00 ET

Chiome Bioscience: Announcements of individual stocks: Start of administration in Phase 1 clinical trials of ADC therapy for cancer treatment ADCT-701.

Jul 28 23:00 ET

Chiome Bioscience: Announcements of individual stock: Business partnership about the development of biosimilar pharmaceuticals with KidsWell Bio Co., Ltd.

Jun 18 03:00 ET

Chiome Bioscience: Notice regarding the monthly exercise status of the 20th Stock Acquisition Rights (with exercise price amendment clause)

Jun 3 02:00 ET

Chiome Bioscience: Presentation of research results using Chiome's antibodies at the 67th Annual Meeting of the Japanese Society of Nephrology

Jun 3 02:00 ET

Chiome Bioscience: Announcement of research results using our antibodies at the 67th Annual Meeting of the Japanese Society of Nephrology

Jun 3 02:00 ET

CHIOME BIOSCIENCE: Supplementary information on financial results for the 1st quarter of the fiscal year ending December 24

May 14 03:00 ET

CHIOME BIOSCIENCE: Unconsolidated financial results for the three months ended March 31, 2024 (Japanese Accounting Standards)

May 14 03:00 ET

CHIOME BIOSCIENCE: Notice Concerning the Recording of Non-Operating Profit

May 14 03:00 ET

CHIOME BIOSCIENCE: Notice regarding the monthly exercise status of the 20th Stock Acquisition Rights (with exercise price amendment clause)

May 1 02:00 ET

CHIOME BIOSCIENCE: Notice Concerning Mass Exercise of the 20th Stock Acquisition Rights (with Exercise Price Amendment Clauses)

Apr 23 02:00 ET

Chiom Bioscience: Notice Concerning the Monthly Exercise Status of the 20th Stock Acquisition Rights (with Exercise Price Amendment Clauses)

Apr 1 02:00 ET

Chiome Biosciences: End of license agreement with ADC Therapeutics

Mar 29 02:00 ET

Chiom Biosciences: Notice of termination of license agreement with ADC Therapeutics due to transition of ADCT-701 clinical trial subjects to NCI

Mar 29 02:00 ET

Chiome Biosciences: Notice regarding patent assessment in China relating to PCDC, a candidate antibody for cancer treatment

Mar 25 03:00 ET